Update shared on27 Aug 2025
Fair value Decreased 2.24%The slight reduction in Olympus’s analyst price target reflects modest declines in both consensus revenue growth and net profit margin forecasts.
What's in the News
- Olympus lowered fiscal year 2026 guidance, with revenue expected at ¥998,000 million (previously ¥999,000 million), operating profit at ¥136,000 million (previously ¥150,000 million), and profit attributable to owners of parent at ¥94,000 million (previously ¥105,000 million).
- Olympus completed no share repurchases under the buyback program announced in May 2025.
- Olympus entered a strategic partnership with Revival Healthcare Capital, co-founding Swan EndoSurgical Inc. for GI endoluminal robotics, with up to $458 million investment tied to milestones, and structured options for acquisition.
- Olympus and FluoGuide A/S announced a non-exclusive collaboration to develop FG001 for tumor imaging in head and neck cancer, supporting the clinical phase and evidence gathering for Olympus’s platforms with no financial impact in 2025.
- Olympus launched SeleCT Screening, an AI-driven emphysema screening program designed to identify severe emphysema patients eligible for bronchoscopic lung volume reduction using its Spiration Valve System.
Valuation Changes
Summary of Valuation Changes for Olympus
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from ¥2168 to ¥2134.
- The Consensus Revenue Growth forecasts for Olympus has fallen from 4.3% per annum to 4.0% per annum.
- The Net Profit Margin for Olympus has fallen slightly from 11.88% to 11.62%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.